Palvella Therapeutics, Inc.
PVLANasdaqCIK 1583648HealthcareFiscal year ends Dec 31
Reports and events: 315 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2807:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-435113 |
| 2026-08-0407:51 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-331574 |
| 2026-08-0407:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-331556 |
| 2026-07-1416:48 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-303307 |
| 2026-06-3007:36 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001104659-26-079087 |
| 2026-06-1608:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-074338 |
| 2026-05-2016:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-232717 |
| 2026-05-1507:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-225317 |
| 2026-05-1307:30 ET | 8-K | 8.01 Other events | 0001193125-26-220607 |
| 2026-05-0709:09 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-210605 |
| 2026-05-0708:30 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-210463 |
| 2026-04-3016:05 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001104659-26-052875 |
| 2026-04-1307:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-151979 |
| 2026-04-0707:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-144540 |
| 2026-03-3108:30 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-133372 |
| 2026-03-3108:00 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-133332 |
| 2026-02-2617:31 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-26-020667 |
| 2026-02-2416:23 ET | 8-K | 2.02 Results of operations | 0001104659-26-019143 |
| 2026-02-2407:55 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-065308 |
| 2026-02-2406:30 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-065159 |
| 2026-01-2916:08 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-029341 |
| 2026-01-1207:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009724 |
| 2025-12-1506:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-120789 |
| 2025-11-1208:33 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-276119 |
| 2025-11-1016:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-274378 |
| 2025-11-0506:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-106591 |
| 2025-09-2406:01 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-092681 |
| 2025-09-0307:31 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-086685 |
| 2025-08-1408:00 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-108438 |
| 2025-08-1407:30 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-108422 |
| 2025-06-1116:05 ET | 8-K | 5.07 Shareholder vote results | 0001104659-25-058532 |
| 2025-05-1507:45 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-071998 |
| 2025-05-1507:31 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-071988 |
| 2025-04-3016:05 ET | DEF 14A | Proxy statementPeriod 2025-06-10 | 0001104659-25-042493 |
| 2025-03-3107:51 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-047212 |
| 2025-03-3107:32 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-047206 |
| 2025-03-0408:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-006013 |
| 2025-01-1406:22 ET | S-1/A | Registration statement, amended | 0001437749-25-001017 |
| 2025-01-1307:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-25-000924 |
| 2024-12-3106:04 ET | S-1 | Registration statement | 0001437749-24-038553 |
| 2024-12-2017:32 ET | SCHEDULE 13D | Ownership report, active investor | 0001437749-24-038167 |
| 2024-12-1621:53 ET | 8-K | 1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.05 Item not in the standard list; 5.06 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-037515 |
| 2024-12-1216:15 ET | 8-K | 3.03 Change to security holders’ rights; 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-037350 |
| 2024-12-0308:30 ET | 8-K | 5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-036506 |
| 2024-11-1316:02 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001437749-24-034891 |
| 2024-11-0617:01 ET | DEF 14A | Proxy statementPeriod 2024-12-02 | 0001437749-24-033669 |
| 2024-10-0308:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-030559 |
| 2024-08-1416:01 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001437749-24-026778 |
| 2024-08-0816:17 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001437749-24-025565 |
| 2024-07-2406:40 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-24-023301 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 28, 2026, 07:31 ET. Listed shows no prices and gives no investment advice.